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Cardiac resistance to growth hormone in uremia.
Background. Cardiovascular disease is a major cause of death
in end-stage renal disease (ESRD). Since growth hormone is
required for maintaining normal cardiac structure and func-
tion and as growth hormone has a salutary effect on cardiac
remodeling in disease, we postulated that if cardiac resistance
to growth hormone develops in chronic renal failure (CRF) this
may predispose to the cardiomyopathy of uremia. We set out
to test whether in CRF there is resistance to the cardiac action
of growth hormone and whether this defect might be caused by
altered growth hormone signaling.
Methods. Growth hormone–deficient (dw/dw) rats and
growth hormone–intact Sprague-Dawley rats underwent a
subtotal nephrectomy or sham operation and pair feeding.
Results. In dw/dw rats treated with growth hormone for
8 days there was a significant increase in insulin-like growth
factor-1 (IGF-1) mRNA levels in controls but this response
was attenuated in CRF. Next, growth hormone–stimulated
Janus kinase-signal transducers and activators of transcription
(JAK2-STAT5) signaling was studied 15 minutes after intra-
venous growth hormone in dw/dw and Sprague-Dawley rats.
Growth hormone receptor, JAK2, STAT5a, and STAT5b pro-
tein levels were unaltered in CRF. Growth hormone–induced
JAK2, growth hormone receptor (GHR), and STAT5 tyro-
sine phosphorylation was significantly depressed in CRF as
was nuclear translocation of phosphorylated STAT5. When rats
were treated with pharmacologic dose growth hormone, STAT5
phosphorylation increased similarly in CRF and control rats.
Conclusion. Uremic rats develop cardiac resistance to growth
hormone caused at least, in part, by a postreceptor defect in
growth hormone–induced signaling that is characterized by im-
paired phosphorylation and nuclear translocation of STAT5.
These findings raise the question whether growth hormone re-
sistance contributes to the cardiac changes of uremia.
Cardiovascular disease (CVD) is common in end-stage
renal disease (ESRD) and accounts for approximately
one half the deaths in this patient population [1, 2] and
it is now apparent that the increase in CVD is present in
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chronic kidney disease even prior to dialysis [1]. Further-
more, tolerance to ischemic insults is reduced in uremia
and this worsens the prognosis [3, 4]. Multiple factors lead
to the development of CVD, including an increase in com-
monly recognized risk factors for cardiac disease, as well
as risk factors peculiar to this patient population [1, 2].
The main cardiac anatomic abnormalities in patients with
chronic renal failure (CRF) include ventricular hyper-
trophy, interstitial expansion and fibrosis, reduced left
ventricular capillary supply, and myocardial calcifica-
tion [5].The increase in interstitial fibrosis and capillary/
myocyte mismatch, abnormalities that reduce the toler-
ance to ischemia, appear to be related to the uremic state
and apparently cannot be attributed to coexisting disease
such as hypertension or diabetes [5, 6]. These cardiac ab-
normalities, including reduced ischemia tolerance [7], are
reproduced in rats with CRF and while the molecular
mechanisms are poorly understood it appears that these
changes reflect a uremic etiology [5].
It has long been recognized that among the hormones
and growth factors involved in the maintenance of normal
cardiac structure and function, growth hormone is essen-
tial [8, 9]. In chronic growth hormone deficiency there is
a decrease in cardiac size, increased large-artery stiffness
and dysfunction of endothelial cells [10], and death from
CVD increases twofold [11]. On the other hand, when
growth hormone is in excess, as in acromegaly, biven-
tricular hypertrophy and interstitial fibrosis develop and
cardiac performance falls [8, 12]. These cardiac abnor-
malities of growth hormone excess or deficiency can be
reversed with correction of the abnormal growth hor-
mone state [12, 13]. Administration of growth hormone
to animals with cardiac disease has a salutary effect on
cardiac remodeling and cardiac output [8, 14]. For ex-
ample administration of growth hormone to rats with
myocardial infarcts can attenuate left ventricular remod-
eling and adaptive fibrosis and improve cardiac function
[14, 15]. Conversely, growth hormone–deficient rats are
more sensitive to ischemic damage [16, 17]. Growth hor-
mone also improves cardiac function in rats and mice with
congestive heart failure [18] and in old rats growth hor-
mone reverses age-related cardiac myofilament dysfunc-
tion [19, 20] and increases regional coronary blood flow
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and capillary density [20]. In view of these animal studies,
growth hormone has been examined in clinical trials of
congestive heart failure but the results have been mixed
and thus inconclusive [21, 22].
In CRF there is resistance to growth hormone and this
contributes to growth retardation and muscle wasting.
[23]. Growth hormone resistance arises in part because
of a defect in growth hormone–mediated Janus kinase-
signal transducers and activators of transcription (JAK-
STAT) signal transduction as shown in liver and skeletal
muscle of uremic rats [24, 25]: other potential causes
includes growth hormone receptor down-regulation, an
inconstant finding, and resistance to insulin-like growth
factor-1 (IGF-1), which is the main mediator of growth
hormone action [23, 26]. Normally binding of growth hor-
mone to its receptor induces the autophosphorylation of
JAK2, a tyrosine kinase associated with the receptor [27,
28]. The activated JAK2 in turn phosphorylates mem-
bers of the STAT family of proteins, namely STAT1,
STAT3, and STAT5a and STAT5b, which then form
dimers that translocate into the nucleus, bind to spe-
cific promoter sequences of growth hormone–dependent
genes and transactivate or repress their transcription. An
intact JAK2-STAT5b signaling pathway is required for
normal body growth [29] and this pathway is required for
mediating growth hormone stimulation of IGF-1 gene ex-
pression [30, 31]. STAT5a, which has 90% sequence ho-
mology with STAT5b, may to a lesser extent also play
a role in mediating growth hormone–stimulated body
growth [29]. The JAK-STAT signaling pathway is regu-
lated by several factors, including signal transducers and
suppressors of cytokine signaling (SOCS), proteins that
are induced by growth hormone and serve as negative
feedback regulators and protein tyrosine phosphatases
that dephosphorylate the activated signaling proteins [32]
Since growth hormone is required for the maintenance
of normal cardiac structure and function and as growth
hormone has a favorable effect on cardiac remodeling
in experimental cardiac disease [8], we postulate that if
growth hormone resistance develops in the heart as it
does in other tissues [23, 24, 26], then this might have a
permissive effect on the cardiac remodeling that occurs in
uremia. In this study we set out to determine whether car-
diac resistance to growth hormone actually develops in
CRF and whether as we have described in liver and skele-
tal muscle [24], this could be caused, at least in part, by
impaired growth hormone–mediated JAK2-STAT5 sig-
nal transduction.
METHODS
Experimental animals and protocols
Growth hormone–deficient (dw/dw) male rats and
pituitary-intact male Sprague-Dawley rats 100 ∼ 120 g in
weight were studied as previously described [24]. The for-
mer were first studied as growth hormone–deficient rats
are far more responsive to the action of exogenous growth
hormone than hormone-replete animals. CRF was estab-
lished by a 5/6 nephrectomy procedure under ketamine
(80 mg/kg) and xylazine (10 mg/kg) anesthesia; first 2/3
of the left kidney was excised and 6 or 9 days later, the
right kidney was removed. In control animals, sham op-
erations were performed and the animals were pair-fed
with the CRF rats.
Growth hormone–stimulated gene expression. After
13 days of CRF, the uremic and control growth hormone–
deficient animals were separated into two groups (six to
eight rats each) and treated for 8 days with vehicle or
recombinant bovine growth hormone (a gift from Mon-
santo Corp., St. Louis, MO, USA). Growth hormone was
given subcutaneously at a dose of 250 lg/kg body weight
twice a day for 41/2 days and then at 125 lg/kg for 31/2
days. On the last day, the rats received two doses of growth
hormone, 125 lg/kg each, or vehicle 5 hours apart. Then,
60 minutes after the last injection they were sacrificed un-
der anesthesia. These time points were chosen in order
to allow sufficient time for growth hormone induction
of IGF-1 [33] and SOCS gene expression [30]. Venous
blood was collected and the heart was excised and stored
at −80◦C.
Growth hormone activated JAK2-STAT5 signal trans-
duction.
Study in growth hormone–deficient rats. CRF and
control animals were studied 16 days after the final
nephrectomy. After an overnight fast the rats were anes-
thetized and growth hormone (30 lg/kg/body weight) or
vehicle was injected into the inferior vena cava through a
midline incision. Fifteen minutes later the heart was col-
lected, trimmed, and frozen in liquid nitrogen and stored
at −80◦C. In another set of experiments a supramaximal
dose of growth hormone, 250 lg/kg, was given to see if the
growth hormone–resistant state could be overcome. The
dose of growth hormone was chosen based on a pilot dose
response experiment in which maximal phosphorylation
of STAT5 was achieved at 125 lg/kg/body weight.
Study in pituitary-intact Sprague-Dawley rats. These
experiments were carried out to determine whether
pituitary-intact rats respond to uremia in the same man-
ner as growth hormone−deficient rats. The rats, six per
group, were studied after 22 days of renal failure and were
sacrificed 10 minutes after the intravenous injection of ve-
hicle or bovine growth hormone, 750 lg/kg/body weight.
Biochemical measurements
Serum creatinine and bicarbonate was measured with
a Beckman LX 20 Analyzer (Beckman Coulter, Inc.,
Fullerton, CA, USA) and tissue protein content by the
Bradford method (Protein Assay Kit) (Bio-Rad Labo-
ratories, Hercules, CA, USA). Serum C-reactive protein
(CRP) levels were determined with a highly sensitive rat
CRP enzyme-linked immunosorbent assay (ELISA) kit.
(Alpha Diagnostic International, Inc., San Antonio, TX,
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USA). Protein tyrosine phosphatase (PTPase) activity
was assayed with the Promega Tyrosine Phosphatase As-
say System that determines the amount of free phosphate
generated from a phosphopeptide substrate in a reaction
by measuring the absorbance of a molybdate:malachite
green:phosphate complex that is formed (Promega Cor-
poration, Madison, WI, USA). In the assay two synthe-
sized phosphopeptides, END (pY)INASL (substrate 1)
and DADE(pY)LIPQQG (substrate 2) acted upon by a
broad array of tyrosine phosphatases, served as substrates
[34]. Frozen gastrocnemius muscle was homogenized in
cold buffer A [1 mmol/L dithiotheito (DTT), 4 mmol/L
ethylenediaminetetraacetic acid (EDTA), 2.5 mmol/L
benzamidine, 1 lmol/L leupeptin, 1 lmol/L pepstatin,
0.15 lmol/L aprotinin, and 2 mmol/L phenylmethylsul-
fonyl fluoride (PMSF) in 25 mmol/L Hepes, pH 7.4],
centrifuged at 350,000g for 30 minutes and the super-
natant was removed. The pellet was solubilized by incu-
bation in 250 uL buffer B (buffer A containing 1% Triton
X-100 and 0.6 mol/L potassium chloride), on ice for
30 minutes and recentrifuged at 150,000g for 1 hour. The
supernatant was collected as the solubilized “particulate”
fraction which contains 90% of the PTPase activity in
muscle [35]. This fraction was dialyzed overnight in buffer
A to remove endogenous phosphate and assayed accord-
ing to the manufacturer’s instructions.
Immunoprecipitation and Western immunoblotting
The antibody against STAT5, which detects both
STAT5a and STAT5b, the anti-JAK2 antibody, and pro-
tein A agarose were from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). The antibody against phos-
photyrosine (clone 4G10) and the antibody against
phospho-STAT5, which is directed against the tyrosine-
phosphorylated forms of both STAT5a and STAT5b,
were from Upstate Biotechnology (Lake Placid, NY,
USA). The growth hormone receptor (GHR) antibody,
raised against the extracellular domain of the growth
hormone receptor, was a gift of W.R. Baumbach [36].
Tissue lysates were prepared by homogenization exactly
as described before [24]. Nuclear extracts were pre-
pared using the NE-PER extraction kit (Pierce, Rock-
ford, IL, USA). For growth hormone receptor and JAK2
immunoprecipitation, 2 mg and 5 mg of protein, re-
spectively, were diluted to 1 mL in immunoprecipitation
buffer [containing 10 mmol/L Tris (pH 7.4), 1% Triton X,
150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L ethylene
glycol tetraacetic acetate (EGTA), 0.2 mmol/L Na3VO4,
0.2 mmol/L PMSF, and 0.5% NP-40] and incubated with
protein A agarose beads on ice for 1 hour and then cen-
trifuged. The supernatant was incubated with the GHR
or JAK2 antibody on ice for 2 hours. Immune complexes
were then adsorbed to protein A agarose beads for 1 hour,
washed three times, and resuspensed in 4× Laemmli sam-
ple buffer.
Cardiac lysates (for direct assay of proteins) or
immunoprecipitates were electrophoresed on a 7.5%
sodium-dodecyl sulfate (SDS) polyacrylamide gel and
electroblotted onto nitrocellulose membranes [24]. Blots
were blocked for 1 hour in TBST buffer [10 mmol/L Tris
(pH 7.4), 138 mmol/L NaCl, 0.05% Tween-20 contain-
ing 5% nonfat dehydrated milk or 1% bovine serum
albumin (BSA)]. Thereafter, the blots of the JAK-2
immunoprecipitates were incubated overnight at 4◦C
with antibodies against phosphotyrosine residues (clone
4G10). The lysate blots were incubated with antibod-
ies directed against GHR, JAK2, STAT5a, STAT5b,
or STAT5a/b, or phospho-STAT5. After washing three
times for 15 minutes in TBST, the blots were incubated
with secondary antirabbit or antimouse antibody conju-
gated to horseradish peroxidase (Santa Cruz Biotech-
nologies) for 1 hour at room temperature and washed
again three times. The signal on the filter was detected
by enhanced chemiluminescence (ECL) (Amersham, Ar-
lington Heights, IL, USA) and exposure to Kodak XAR
film (Eastman Kodak Co., Rochester, NY, USA). On sev-
eral occasions the nitrocellulose blots were striped by
Re-Blot Plus antibody stripping solution (Chemicon In-
ternational, Inc., Temecula, CA, USA) and then reprobed
with a different antibody. Protein levels were quantitated
densitometrically with a Fluor-S digital image analyzer
and Multianalyst software (Bio-Rad Laboratories). Phos-
phorylated protein readings are expressed as a percent of
the average control value. Relative phosphorylated pro-
tein levels refer to the phosphorylated protein reading
normalized for the respective protein reading.
Real-time quantitative reverse transcription-polymerase
chain reaction (RT-PCR) assay
For measuring GHR, IGF-1, SOCS1, SOCS2, SOCS3,
and CIS gene expression, total RNA was extracted from
myocardium using Tri Reagent (Sigma Chemical Co., St.
Louis, MO, USA). Extracted RNA with an optical density
(OD)260/OD280 ratio greater than 1.8 was used for cDNA
synthesis by reverse transcription [37]. The resultant
cDNA was then analyzed by real-time PCR with SYBR
green dye as the detection agent according to the manu-
facturer’s instructions [37] with an ABI PRISM 7900HT
Sequence Detection System using SDS 2.1 Software (Ap-
plied Biosystems, Foster City, CA, USA). The following
cycling parameters were used: 95◦C for 10 minutes; 95◦C
for 15 seconds → 60◦C for 1 minute for 40 cycles. To quan-
titate PCR products and to confirm the integrity of RNAs,
the housekeeping gene glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) or b-actin was coamplified. The
primer sequences for assaying GHR, IGF-1, SOCS1,
SOCS2, SOCS3, CIS, and GAPDH transcripts were as
previously described [25]. The sequences for the b-actin
primers were forward (5′-3′) 3′-CAGGTCATCACCATT
GGCAATGAGC and reverse (3′-5′) CGGATGTCCAC
GTCACACTTCATGA.
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Table 1. Serum biochemical levels in rats with chronic renal failure (CRF) and their pair-fed controls treated with growth hormone or vehicle for
8 days
Pair fed Control CRF
Vehicle Growth hormone Vehicle Growth hormone
Serum creatinine mg/dL 0.30 ± 0a 0.33 ± 0.07a 0.87 ± 0.03b 1.0 ± 0.14b
Blood urea nitrogen mg/dL 11 ± 0.7a 10 ± 1.3a 42. ± 2.4b 47 ± 4.8b
CO2 mmol/L 25 ± 0.3a 26 ± 0.7a 26 ± 0.8a 27 ± 0.4a
The results are the mean ± SEM of seven to eight rats/group. Dissimilar superscript letters indicate significant difference between groups in each row (P < 0.05).
Table 2. Real-time polymerase chain reaction (PCR) assay for relative quantification of insulin-like growth factor-1 (IGF-1) mRNA in heart of
chronic renal failure (CRF) and pair-fed control rats treated with growth hormone or vehicle for 8 days
CT IGF-1 CT b-actin CT IGF-1-b-actin CT CT – CT control IGF 1 relative to control
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean (range)
Control vehicle 24.1 ± 0.3 21.7 ± 0.5 a3.3 ± 0.6 0.00 ± 0.6 100 (153–65)
Control growth hormone 24.5 ± 0.5 22.3 ± 0.6 b2.2 ± 0.8 −1.06 ± 0.8 212 (365–118)
CRF vehicle 25.3 ± 0.4 21.9 ± 0.7 a3.4 ± 0.8 0.14 ± 0.8 95 (161–51)
CRF growth hormone 24.6 ± 0.2 21.7 ± 0.5 a2.9 ± 0.6 −0.36 ± 0.6 128 (192–86)
Rats with CRF or pair-fed controls were treated with bovine growth hormone or vehicle for 8 days (six to eight rats/group). On the last day, growth hormone or
vehicle was given 5 hours and then again 1 hour prior to sacrifice. mRNA levels were measured by quantitative real-time PCR. The amount of the IGF-1 transcript
relative to the b-actin transcript was determined by the comparative CT method. Dissimilar superscript letters indicate differences between groups (P < 0.05). Groups
with common superscript letters are similar.
The relative efficiencies of the GHR, IGF-1, and SOCS
primers sets and the GAPDH primer pair were tested
by subjecting serial dilutions of RNA samples extracted
from primers the heart to real time RT-PCR analysis [37].
After establishing that the efficiencies of amplification of
the gene of interest and the housekeeping gene were ap-
proximately equal, as was true for all the genes analyzed,
the amount of the transcripts for the specific gene rela-
tive to the GAPDH or b-actin transcript was determined
by the comparative CT method. This method is similar
to the relative standard curve method, except that it uses
arithmetic formulas to obtain the same result for rela-
tive quantitation [37]. CT , or threshold cycle, is the PCR
cycle at which the amplified target can first be detected
above baseline. CT represents the difference between
the threshold cycles for the target and reference genes.
The amount of target gene, normalized to an endogenous
housekeeping gene and relative to a calibrator is given by
the following formula: -fold induction = 2C T, where
CT = (CT GI (unknown sample) − CT GAPDH (un-
known sample) − (CT GI (pair-fed control heart) − CT
GAPDH (pair-fed control heart), where GI represents
the gene of interest (e.g., GHR). Each sample was ana-
lyzed in triplicate in individual assays performed on two
or more occasions.
Data analysis and statistics
For comparison of two normally distributed groups the
two-tailed unpaired Student t tests was applied; compar-
isons between more than two groups were made by one-
way analysis of variance (ANOVA) followed by pair-
wise multiple comparison with the Holms t test [38].
For comparing more than two nonnormally distributed
groups the Kruskal-Wallis statistic was applied followed
by the Student-Newman-Keuls test to distinguish be-
tween groups [38]. Data are given as mean ± SEM or
range. A P value of <0.05 was considered statistically
significant.
RESULTS
Effect of uremia and growth hormone treatment
on IGF-1, SOCS gene, and GHR expression
In the 5/6 nephrectomized growth hormone–deficient
rats there was a significant increase in the serum crea-
tinine and urea nitrogen levels compared to the pair-
fed control values, while the serum bicarbonate lev-
els were essentially unchanged (Table 1). Heart weight
was increased in the CRF rats (0.5 ±.037 versus 0.39
± 0.011 mg) (P < 0.01). The serum CRP levels were
modestly elevated in the CRF rats (204 ± 7 versus
171 ± 5 pmol/L) (P < 0.05). In the myocardium, al-
though basal IGF-1 mRNA levels were similar in the
two groups, there was evidence of growth hormone resis-
tance for although growth hormone treatment induced
a significant twofold increase in IGF-1 mRNA levels
in the pair-fed control group, it failed to increase the
mRNA levels significantly in the CRF group (Table 2).
Growth hormone receptor mRNA levels in the vehicle-
treated CRF and pair-fed control rats did not differ
and were not significantly altered by growth hormone
therapy. Similarly basal cardiac SOCS1, SOCS2, SOCS3,
and CIS mRNA levels were unaltered by CRF, as was
the response to growth hormone treatment which in-
creased CIS expression to a similar extent in both groups
(Table 3). These findings differ from our previous find-
ings in liver and skeletal muscle. In liver, basal SOCS2
and SOCS3 mRNA levels were elevated and following
growth hormone treatment there was an exaggerated
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Table 3. Effects of chronic renal failure (CRF) and growth hormone treatment on cardiac suppressors of cytokine signaling (SOCS) and growth
hormone receptor (GHR) mRNA levels
mRNA Pair-fed vehicle Pair-fed growth hormone CRF vehicle CRF growth hormone
GHR
CT a6.9 ± 0.2 a6.9 ± 0.4 a7 ± 0.3 a7.1 ± 0.4
Relative value 100 (117–85) 101 (127–76) 92 (110–73) 83 (108–63)
SOCS1
CT b,c14.4 ± 0.5 b14 ± 0.4 a,c14.6 ± 0.6 a15 ± 0.3
Relative value 100 (145–69) 135 (175–99) 88 (130–59) 67 (103–64)
SOCS2
CT a10.7 ± 0.4 a11.0 ± 0.6 a11.1 ± 0.3 a10.6 ± 0.7
Relative value 100 (128–78) 82 (122–55) 76 (96–61) 106 (175–65)
SOCS3
CT a,b12 ± 0.3 a,b12 ± 0.3 b12.2 ± 0.3 a11.7 ± 0.3
Relative value 100 (129–77) 105 (129–86) 91 (113–73) 124 (150–102)
CIS
CT a5.4 ± 0.7 b4.4 ± 0.6 a5.7 ± 0.5 a,b4.9 ± 1.0
Relative value 100 (160–62) 218 (325–136) 82 (116–58) 149 (283–69)
The amount of the transcripts for each gene relative to the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcript was determined by the comparative
CT method. The CT results are given as the mean ± SD of six to eight rats/group. The expression of the gene of interest relative to its expression in the pair-fed
vehicle-treated control group, that is its relative value, is given as the mean and range. Dissimilar superscript letters indicate significant difference between groups in
each row (P < 0.05). Groups with common superscript letters are similar.
increase in SOCS2 expression [24]. In skeletal muscle ob-
tained from the same animals used in the present study,
growth hormone stimulated SOCS2 expression was in-
creased in CRF animals [25]
Growth hormone receptor, JAK2, and STAT5
protein abundance and growth hormone–mediated
JAK2-STAT5 signal transduction in growth hormone–
deficient rats with CRF
In these experiments the serum creatinine levels were
also elevated threefold in the CRF rats compared to the
pair-fed controls and the serum bicarbonate levels were
not reduced (data not shown). Western immunoblots of
whole cardiac lysates showed that the GHR, JAK2, and
STAT5a and STAT5b protein levels were similar in the
CRF and pair-fed control groups (Fig. 1A). STAT5 tyro-
sine phosphorylation measured with an antibody that de-
tects both phospho-STAT5a and phospho-STAT5b was
negligible or absent in the vehicle-treated rats of both
groups. In contrast, 15 minutes after the intravenous ad-
ministration of growth hormone, 30 lg/kg, phosphoryla-
tion of STAT5 was evident in both groups of rats, though
attenuated in the CRF group (Fig. 1B). The relative phos-
phorylation of STAT5a/b corrected for the protein level
was depressed and averaged 55% ± 6% of the control
value (P < 0.001)
After undergoing phosphorylation, phospho-STATS
translocate into the nucleus. Accordingly, to see whether
the nuclear levels of phospho-STAT5 were also re-
duced, we measured phospho-STAT5a/b levels in nuclear
extracts obtained 15 minutes after growth hormone,
30 lg/kg, administration. Using the same phospho-
STAT5 antibody as above, we found that the phospho-
STAT5a/b was significantly reduced in the nuclei of
growth hormone–treated CRF animals compared to the
controls (70 ± 6 versus 100 ± 6 arbitrary units) (P <
CRF-15min GH Con-15min GH Pooled vehicle
CRF Con
GHR
JAK2
STAT5a
STAT5b
CRF-15min GH Con-15min GH Pooled vehicle
CRF Con
STAT5a/b
p-STAT5a/b
B
A
Fig. 1. (A) Cardiac growth hormone receptor (GHR), Janus kinase
(JAK2), signal transducers and activators of transcription (STAT5a and
STAT5b) protein levels are unchanged in chronic renal failure (CRF).
Protein levels were determined with Western immunoblots of cardiac
lysates from CRF and pair-fed control rats treated with growth hor-
mone or vehicle 15 minutes before sacrifice. (B) Tyrosine phosphory-
lation of STAT5a/b in response to growth hormone is impaired in the
heart in CRF. STAT5 and phosphorylated STAT5 levels were assayed
by Western immunoblots with antibodies that recognizes both STAT5a
and STAT5b or both tyrosine phosphorylated STATs. Hearts were col-
lected from CRF and control rats 15 minutes after an intravenous bolus
of vehicle or bovine growth hormone, 30 ug/kg.
0.05) (Fig. 2). Next, to establish whether this repre-
sented a reduction in STAT5a or STAT5b translocation,
we measured the levels of STAT5a and STAT5b pro-
tein in the nucleus of the CRF and control groups with
the protein-specific antibodies. Interestingly, while the
nuclear STAT5a levels were similar in the two groups
of animals (92 ± 3 versus 100 ± 4 arbitrary units, re-
spectively), STAT5b levels were reduced significantly by
56% in CRF (44 ± 5 versus 100 ± 6 arbitrary densitom-
etry units) (P < 0.001) (Fig. 2). Taken together, this sug-
gests that the depressed cellular STAT5 phosphorylation
reflects attenuation of STAT5b phosphorylation only, as
STAT5b is needed for growth hormone–mediated IGF-1
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CRF-GH Con-GH
STAT5b
STAT5a
p-STAT5a/b
Fig. 2. Nuclear levels of signal transducer and activator of transcrip-
tion 5b (STAT5b) and phosphorylated STAT5a/b are lower in chronic
renal failure (CRF) rats compared to controls 15 minutes after growth
hormone (GH) administration, while levels of STAT5a are unchanged.
Growth hormone, 3 lg/100 g, or vehicle was given intravenously as a
bolus to growth hormone–deficient CRF and control rats. Western im-
munoblots of nuclear protein extracts were performed using antibodies
against p-STAT5a/b and STAT5a and STAT5b.
CRF-GH Con-GH
STAT5
p-STAT5
Pooled vehicle
CRF Con
Fig. 3. Signal transducers and activators of transcription (STAT5)
phosphorylation following high dose growth hormone (GH) treatment.
Chronic renal failure (CRF) and pair-fed control growth hormone–
deficient rats were given an intravenous bolus of growth hormone,
25 lg/100 g and the heart was collected 10 minutes later.
gene transcription [31], this provides an explanation for
the resistance to growth hormone–induced IGF-1 gene
expression in CRF.
Next, to determine whether the growth hormone re-
sistance in the heart can be overcome by a supramax-
imal dose of growth hormone, we measured STAT5
phosphorylation in heart collected 10 minutes after an in-
travenous bolus of bovine growth hormone 250 lg/kg. At
this growth hormone dose phospho-STAT5 levels were
similar in the CRF and control groups, 107 ± 4 versus
100 ± 5 relative arbitrary units, respectively (Fig. 3).
Growth hormone–mediated JAK2-STAT5
signal transduction in pituitary-intact
Sprague-Dawley with renal failure
The serum creatinine levels were elevated significantly
in the CRF rats compared to the pair-fed controls, 1.8 ±
0.3 versus 0.3 ± 0.02 mg/dL, while the total CO2 lev-
els were not significantly different, 27 ± 0.6 versus
24 ± 1.2 mmol/L. As observed in the growth hormone–
deficient rats, the GHR, JAK2, and STAT5 protein lev-
els were similar in the myocardium of CRF and pair-fed
control rats (Fig. 4A). In the vehicle-treated rats tyro-
sine phosphorylation of these proteins was negligible or
absent, while 10 minutes after an intravenous bolus of
bovine growth hormone, 750 lg/kg body weight, tyrosine
phosphorylation of these proteins was pronounced. Of
note, however, in the CRF group, phosphorylation of the
CRF-15min GH Con-15min GH Pooled vehicle
CRF Con
p-GHR
p-JAK2
p-STAT5
B
CRF-15min GH Con-15min GH Pooled vehicle
CRF Con
GHR
JAK2
STAT5a/b
A
p-GHR/
GHR
p-JAK2/
JAK2
p-STAT5/
STAT5
C
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*
*
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Fig. 4. Growth hormone receptor (GHR), Janus kinase (JAK2), and
signal transducers and activators of transcription (STAT5) protein lev-
els are unchanged in the heart of Sprague-Dawley rats with chronic re-
nal failure (CRF), but growth hormone–induced protein tyrosine phos-
phorylation of these proteins is impaired. (A) Western immunoblots
of GHR, JAK2, and STAT5 protein levels in lysates prepared from
the heart of CRF and control pair-fed rats obtained 10 minutes after
an intravenous bolus of growth hormone, 250 lg/kg, or vehicle. Sam-
ples from vehicle treated animals were pooled for this immunoblot. (B)
Tyrosine-phosphorylated GHR, JAK2, and STAT5 levels in the same
samples as shown in Figure 3A. The phospho-GHR and phospho-JAK2
were detected in immunoblots of GHR and JAK2 immunoprecipitates
with ant-phosphotyrosine antibody (clone 4G10). Phospho-STAT5 was
detected without immunoprecipitation using a phospho-STAT5 specific
antibody (six rats/group). (C) Relative phosphorylation of GHR, JAK2,
and STAT5 proteins 10 minutes after bovine growth hormone bolus in
CRF and control animals. ∗P < 0.05. Phospho-protein signals were cor-
rected for the specific protein levels and the ratios were normalized
to the pair-fed control mean, which was assigned a value of 100. Bars
indicate mean ± SEM.
GHR, JAK2, and STAT5 proteins was depressed signifi-
cantly and to a similar extent, 40% to 48%, compared to
the control values (Fig. 4B and C).
PTPase activity
To determine whether an increase of PTPase activity
might be a cause of the reduced level of growth hormone–
induced phosphorylated proteins we measured tyrosine
phosphatase activity in solubilized particulate fractions
prepared from the heart of growth hormone–deficient
rats; most cellular tyrosine phosphatase activity resides
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in the particulate fraction [35]. We found no difference in
activity between the study groups using the two different
peptide substrates described earlier. For substrate 1 the
values for the CRF and control groups averaged 185 ±
35 versus 191 ± 33 and for substrate 2, 188 ± 38 versus
187 ± 40 pmol/ug protein, respectively.
DISCUSSION
The resistance to growth hormone that develops in ure-
mia has significant clinical consequences. In children it
is a major cause of impaired body growth and in adults
growth hormone resistance contributes to loss of muscle
mass [23, 26]. Since as discussed earlier growth hormone
plays an essential role in the maintenance of normal car-
diac structure and function [8, 9] and as growth hor-
mone has a salutary effect on remodeling after injury
[8, 14], we proposed that if resistance to growth hor-
mone develops in the heart in uremia, then this may
well predispose to the CVD and reduced ischemia tol-
erance that is common in advanced renal failure [1, 2,
7]. Accordingly, we set out to determine whether car-
diac resistance to growth hormone actually develops in
uremia and if present, whether this could be due to de-
fective growth hormone–mediated JAK2-STAT5 signal
transduction. Studying growth hormone–deficient rats
with CRF we found growth hormone stimulated IGF-
1 gene expression was attenuated in the heart. Since the
CRF rats did not develop an acidosis, this insensitivity to
growth hormone could not be attributed to an alteration
in systemic acid-base status.
The hearts of these CRF rats were enlarged, which to
a considerable extent reflects a response to hyperten-
sion, volume overload and increased angiotensin levels
[1, 2]. Since these factors stimulate cardiac IGF-1 mRNA
expression [39–41], they cannot account for the attenu-
ated IGF-1 response to growth hormone treatment. Re-
sistance could not be attributed to changes in cardiac
GHR or signaling protein levels for GHR, JAK2, and
STAT5a and STAT5b levels were similar in CRF and
pair-fed control rats. However, growth hormone–induced
tyrosine phosphorylation of STAT5 was impaired in the
uremic state and relative STAT5 tyrosine phosphoryla-
tion was reduced by approximately half. Nuclear levels
of phosphorylated STAT5 were also significantly re-
duced, presumably reflecting depressed translocation of
the phosphorylated protein from the cytoplasm. Anal-
ysis of the nuclear STAT5 protein forms revealed that
STAT5b levels were reduced while STAT5a levels were
unaltered. Since cytosolic tyrosine phosphorylation of
these proteins is required for nuclear translocation, it ap-
pears that phosphorylation of STAT5b and not STAT5a
is impaired in uremic rats. As STAT5b is an essential in-
termediate in growth hormone−stimulated IGF-1 gene
transcription [30, 31, 42], we conclude that this defect in
growth hormone–mediated signal transduction is a cause
of the cardiac resistance to growth hormone–induced
IGF-1 expression in CRF. Interestingly while growth
hormone–induced IGF-1 gene expression was attenu-
ated, growth hormone–stimulated expression of the CIS
gene, a member of the SOCS family also induced via the
STAT5b pathway [30], was not altered in uremia. This
indicates that the resistance to growth hormone is partial
and suggests that uremia does not affect all the signaling
pathways activated by growth hormone.
Growth hormone induced STAT5 phosphorylation was
also impaired in the heart of growth hormone–intact
Sprague-Dawley rats. In these animals we found that this
signaling defect could be traced to more proximal events,
tyrosine phosphorylation of the GHR and JAK2 were sig-
nificantly reduced. In an earlier study of growth hormone
signaling in the liver of Sprague-Dawley rats, we found
that growth hormone induced JAK2-STAT5 phosphory-
lation and IGF-1 gene expression were also depressed in
uremia [24].
Other cytokines and growth factors besides growth hor-
mone activate the JAK-STAT pathway in the heart and
include angiotensin II, IGF-I, leukemia-inhibiting factor
(LIF), and cardiotropin [43]. The JAK-STATs are also
activated by mechanical stress, ischemia, and acute my-
ocardial injury and thus the JAK-STAT signaling path-
way is regarded as an important signaling pathway in
the heart [43]. The JAK-STATS activated by these var-
ious stimuli differ. Angiotensin II which is up-regulated
in the rat with reduced renal mass, signals through sev-
eral janus kinases (JAK1, JAK2, and Tyk2) that phos-
phorylate STAT1, STAT2, STAT3, 5a and 6, but not to
our knowledge STAT5b [44]. Thus the attenuated JAK2-
STAT5 phosphorylation does not appear to be related to
the increased angiotensin II levels. In any event, in the
present study basal STAT 5 phosphorylation was not af-
fected in uremia and it was only after growth hormone
was administered was it apparent that STAT5 phosphory-
lation and nuclear translocation of STAT5b was impaired.
It is noteworthy that when we treated rats with supra-
maximal doses of growth hormone the signaling defect
was overcome, STAT5 phosphorylation increased to a
similar level in CRF and control rats. If this is followed
by an increase in IGF-1 gene and protein expression then
this may be relevant to the clinical use of pharmacologic
doses of growth hormone to promote body growth or
muscle wasting in uremia and raises for consideration the
possibility that treating ESRD patients with excessively
large growth hormone doses may lead to adverse cardiac
effects, including cardiac hypertrophy and interstitial fi-
brosis as occurs in acromegaly [8]. In this regard Jensen
et al [45] noted a significant increase in left ventricular
mass without any effect on cardiac function in ESRD
adults treated with large doses of growth hormone for
6 months.
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While most actions of growth hormone are me-
diated through IGF-1, growth hormone also has di-
rect actions on cardiomyocytes, including stimulation
of IGF-1 gene expression, cellular hypertrophy, in-
creased protein synthesis and fatty acid uptake, and
depression of glucose transport [46]. These are medi-
ated through several signaling pathways, including the
JAK2-STAT, JAK2/phosphatidylinositol 3′ (PI3) kinase
and JAK2/mitogen-activated protein (MAP) kinase path-
ways [27, 28]. Indirect actions mediated through IGF-1 in-
clude increased cardiomyocyte contractility, proliferation
and hypertrophy, and protection against programmed cell
death [47]. In respect to the heart in uremia, there is to
our knowledge, no published information regarding the
impact of renal failure on the sensitivity of the heart to
growth hormone, though as discussed earlier, treatment
with pharmacologic doses of growth hormone does cause
an increase in heart size [45]. On the other hand, there
is evidence that cardiac resistance to IGF-1 develops in
uremia. Qing et al [48] reported that IGF-1–stimulated
protein synthesis is depressed in cardiomyocytes isolated
from uremic rats and attributed this to elevated basal
cytosolic calcium levels. Thus, the cardiac resistance to
growth hormone–stimulated IGF-1 gene transcription
taken together with the insensitivity to IGF-1 action sug-
gests that uremia may have a more severe impact on the
cardiac response to growth hormone than might other-
wise have been anticipated. Normally the action of IGF-1
on the heart is modulated by circulating and local insulin-
like growth factor binding proteins (IGFBPs) that bind
IGF-1 and reduce its immediate bioavailibility. In ure-
mia circulating low-molecular-weight IGFBPs, especially
IGFBP-1 and -2 and fragments of IGFBP-3, accumulate
and further reduce IGF-1 bioavailabity [23, 24, 26]. This
possibly together with an increase in local cardiac IGF-
BPs and impaired IGF-1 signal transduction [49] likely
contributes to the cardiac IGF-1 resistance of uremia.
The mechanisms accounting for the attenuated growth
hormone activated JAK-STAT signaling in the heart of
rats with CRF is unclear. Normal regulation of this signal-
ing pathway involves multiple biochemical events. These
include down-regulation of JAK2 activation of STAT pro-
teins by members of the SOCS family, namely SOCS1,
SOCS2, SOCS3, and CIS, dephosphorylation of activated
signaling proteins by tyrosine phosphatases, ubiquitina-
tion, internalization and degradation of the dephospho-
rlated GHR, and reduced affinity of activated STATS
for their DNA binding sequences through the action
of protein inhibitors of activated STATS (PIAS) [32].
Cross-talk between other cytokines and growth factors
is another physiologic control mechanism. In an ear-
lier study of growth hormone–resistant uremic Sprague-
Dawley rats, we examined growth hormone–mediated
JAK-STAT signal transduction in the liver and found that
it was markedly attenuated. In addition to the impaired
phosphorylation and nuclear translocation of STAT5,
there was impaired JAK2 phosphorylation and the ex-
pression of SOCS2 and SOCS3 mRNA was increased. We
attributed the impaired JAK-STAT phosphorylation, at
least in part, to the inhibitory action of the suppressors of
cytokine signaling. Similarly, we have found that SOCS2
mRNA levels are elevated in the skeletal muscle of ure-
mic growth hormone–deficient rats following growth hor-
mone treatment, the same rats used in the present study
[24, 25], Furthermore, skeletal muscle PTPase activity
was increased, raising the possibility that heightened de-
phosphorylation may be a cause of the attenuated JAK-
STAT phosphorylation. In the current study, though, the
impaired phosphorylation and nuclear translocation of
STAT5 in heart could not be attributed to increased PT-
Pases activity or increased SOCS mRNA expression since
these parameters were unaltered. It should be noted,
however, that it is well documented that there are tissue
differences in the way in which the growth hormone sig-
naling pathways responds to disease. For example Hong-
Brown et al [50], studying sepsis induced growth hormone
resistance in liver and skeletal muscle found that while
growth hormone–induced STAT5 phosphorylation was
depressed in liver, it was unaffected in muscle.
CONCLUSION
We have uncovered an abnormality in growth
hormone–stimulated IGF-1 gene expression in the heart
of rats with CRF that appears to be caused, at least in part,
by a postreceptor defect in growth hormone–mediated
JAK2-STAT5 signal transduction. In particular, we found
that while growth hormone receptor protein levels are un-
changed in uremia, JAK2-mediated STAT5 phosphoryla-
tion and nuclear translocation of STAT5b are depressed.
Since STAT5b activation and nuclear translocation are
essential steps in the mediation of growth hormone stimu-
lation of IGF-1 transcription, it appears that these signal-
ing defects are a cause of the growth hormone resistance
observed. Since growth hormone, largely through the ac-
tion of IGF-1, is essential for the maintenance of normal
cardiac structure and function and as growth hormone de-
ficiency predisposes to CVD, we offer for consideration
the postulate that the cardiac growth hormone–resistant
state may contribute to the increase in CVD prevalent in
patients with advanced renal failure.
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